Outcomes That Matter to Adolescents With Continuous Headache Due to Chronic Migraine and Their Parents
暂无分享,去创建一个
[1] B. Grimes,et al. Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents. , 2020, Pediatric neurology.
[2] S. Powers,et al. Clinic-based characterization of continuous headache in children and adolescents: Comparing youth with chronic migraine to those with new daily persistent headache , 2020, Cephalalgia : an international journal of headache.
[3] R. Lipton,et al. Fremanezumab for preventive treatment of migraine , 2018, Neurology.
[4] R. Lipton,et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults , 2018, Cephalalgia : an international journal of headache.
[5] D. Dodick,et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine , 2018, Cephalalgia : an international journal of headache.
[6] P. Goadsby,et al. Pediatric Migraine Prevention-First, Do No Harm. , 2017, JAMA neurology.
[7] S. Powers,et al. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine , 2017, The New England journal of medicine.
[8] T. Palermo,et al. Adolescent and Parent Treatment Goals in an Internet-Delivered Chronic Pain Self-Management Program: Does Agreement of Treatment Goals Matter? , 2016, Journal of pediatric psychology.
[9] S. Powers,et al. The Childhood and Adolescent Migraine Prevention (CHAMP) Study: A Report on Baseline Characteristics of Participants , 2016, Headache.
[10] R. Lipton,et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study , 2015, The Lancet Neurology.
[11] S. Powers,et al. Childhood and Adolescent Migraine Prevention (CHAMP) Study: A Double‐Blinded, Placebo‐Controlled, Comparative Effectiveness Study of Amitriptyline, Topiramate, and Placebo in the Prevention of Childhood and Adolescent Migraine , 2013, Headache.
[12] M. Bigal,et al. Migraine and migraine subtypes in preadolescent children , 2012, Neurology.
[13] H. Diener,et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial , 2010, Cephalalgia : an international journal of headache.
[14] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[15] A. Pakalnis,et al. Emotional Problems and Prevalence of Medication Overuse in Pediatric Chronic Daily Headache , 2007, Journal of child neurology.
[16] H. Diener,et al. Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study , 2007, Cephalalgia : an international journal of headache.
[17] R. Lipton,et al. Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2007, Headache.
[18] R. Lipton,et al. Primary chronic daily headache and its subtypes in adolescents and adults , 2004, Neurology.
[19] S. Powers,et al. PedMIDAS: Development of a questionnaire to assess disability of migraines in children , 2001, Neurology.
[20] S. Powers,et al. Characterization of chronic daily headaches in children in a multidisciplinary headache center , 2001, Neurology.
[21] M. Arnold. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.